A Phase 1 interventional study of PEGylated uricase and F012 placebo in Hyperuricemia With or Without Gout and Gout, sponsored by The Affiliated Hospital of Qingdao University. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by The Affiliated Hospital of Qingdao University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.
Among the 49 studies in Gout with a site in China, this one is the 35th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2024, is one of 16 in phase 1, and was the 49th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Huashan Hospital · Sites in China
Ages 18–70
Shenyang Sunshine Pharmaceutical Co., LTD. · Sites in China
Ages 18–65
Shanghai Institute Of Biological Products · Sites in China
Ages 18–70
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 9 · Phase 3 10 · Phase 4 3
First in 2010; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 93 across the 44 interventional studies, 350 across the 5 observational. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 49 have an industry lead sponsor. The 10 most frequent:
The Affiliated Hospital of Qingdao University is the lead sponsor of 150 studies on the registry; 56 are open to participants now.
The Affiliated Hospital of Qingdao University has 3 studies filed under Gout — fewer than ten, so there is no comparison to draw.
5 of the studies in Gout with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07414394Phase 3Innovent Biologics Technology Limited (Shanghai R&D Center)Tigulixostat (IBI128) vs Febuxostat in Gout | 2027-04-30 |
| NCT06629376Shenyang Sunshine Pharmaceutical Co., LTD.Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia | 2026-12-20 |
| NCT06298071Shanghai Institute Of Biological ProductsA Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. | 2026-12-30 |
| NCT07587684Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Study of IN026 in Participants With Refractory Gout | 2027-08 |
| NCT07326839XueMei GuoOrlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT | 2027-11-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in Gout with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled single dose escalation (SAD) study conducted in patients with hyperuricemia with or without gout. The plan is to conduct ramp ups in 5 dose groups of 1mg, 2mg, 4mg, 6mg, and 8mg (adjustable during the study), with 8 subjects in each dose group and a total of 40 subjects. The sentinel method will be used for each dose group, with 2 subjects in the first group (1A+1P) followed by 6 subjects in the second group (5A+1P), to observe safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous injection of placebo
Drug: F012 placebo
Single intravenous injection of F012
Drug: PEGylated uricase
Dilute F012 into 0.9% sodium chloride injection solution. Inject 1mg, 2mg, and 4mg dose groups intravenously with a syringe pump, and 6mg and 8mg dose groups intravenously for at least 2 hours.
Dilute placebo into 0.9% sodium chloride injection solution. Inject 1mg, 2mg, and 4mg dose groups intravenously with a syringe pump, and 6mg and 8mg dose groups intravenously for at least 2 hours.
Incidence of Treatment-Emergent Adverse Event and Serious Adverse Events
Time frame: From dosing through Day 71
Plasma Concentration of PEGylated uricase
Time frame: Pre-dosing, immediately after the end of infusion, and 3, 4 , 8 , 12, 24 , 48 , 72 , 168 , 504 , 672 , 840 hours after dosing
Maximum Serum Concentration (Cmax)
Time frame: From start infusion through 840h(D36) after dosing
Area Under the Serum Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC0-t)
Time frame: From start infusion through 840h(D36) after dosing
Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC0-∞)
Time frame: From start infusion through 840h(D36) after dosing
Time to Maximum Observed Serum Concentration (Tmax)
Time frame: From start infusion through 840h(D36) after dosing
Terminal Half-Life (t1/2)
Time frame: From start infusion through 840h(D36) after dosing
Serum Uric Acid Concentration
Time frame: Pre-dosing, immediately after the end of infusion, and 3, 4 , 8 , 12, 24 , 72, 168 , 504,672,840 hours after dosing
Number of Participants With Anti-Drug Antibodies
Time frame: Pre-dosing and 168, 336, 504 , 840, 1680 hours after dosing
Change From Baseline in QT Interval Corrected for Heart Rate (QTcF)
Time frame: Pre-dosing and 2, 3 , 4, 8, 24 , 48 hours after dosing
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Jun 2025, 12 months.
Of 40 phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 12 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Qingdao University →